Last reviewed · How we verify
⁸⁹Zr-Df-IAB22M2C Infusion
⁸⁹Zr-Df-IAB22M2C Infusion is a Small molecule drug developed by ImaginAb, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | ⁸⁹Zr-Df-IAB22M2C Infusion |
|---|---|
| Sponsor | ImaginAb, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) (PHASE1)
- CD8 Minibody Repeatability Study (PHASE2)
- Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (PHASE2)
- ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors (PHASE2)
- ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ⁸⁹Zr-Df-IAB22M2C Infusion CI brief — competitive landscape report
- ⁸⁹Zr-Df-IAB22M2C Infusion updates RSS · CI watch RSS
- ImaginAb, Inc. portfolio CI
Frequently asked questions about ⁸⁹Zr-Df-IAB22M2C Infusion
What is ⁸⁹Zr-Df-IAB22M2C Infusion?
⁸⁹Zr-Df-IAB22M2C Infusion is a Small molecule drug developed by ImaginAb, Inc..
Who makes ⁸⁹Zr-Df-IAB22M2C Infusion?
⁸⁹Zr-Df-IAB22M2C Infusion is developed by ImaginAb, Inc. (see full ImaginAb, Inc. pipeline at /company/imaginab-inc).
What development phase is ⁸⁹Zr-Df-IAB22M2C Infusion in?
⁸⁹Zr-Df-IAB22M2C Infusion is in Phase 1.
Related
- Manufacturer: ImaginAb, Inc. — full pipeline
- Compare: ⁸⁹Zr-Df-IAB22M2C Infusion vs similar drugs
- Pricing: ⁸⁹Zr-Df-IAB22M2C Infusion cost, discount & access